Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ARS fallout

Osiris Therapeutics Inc. hit the jackpot last Friday, winning a $224.7 million contract from the U.S. Department of Defense to develop and stockpile the company's Prochymal to treat acute radiation sickness (ARS). But competitor Cleveland BioLabs Inc. - which had applied for the contract but wasn't chosen - believes its CBLB502 has practical advantages that will give it an edge in future contracts.

C. Randal Mills, Osiris' president and CEO, told BioCentury that about two years ago the company decided to pursue the formulation of mesenchymal stem cells (MSCs) to treat ARS after

Read the full 928 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE